Interleukin-5 in the pathophysiology of severe asthma

C Pelaia, G Paoletti, F Puggioni, F Racca… - Frontiers in …, 2019 - frontiersin.org
Interleukin-5 (IL-5) exerts a central pathogenic role in differentiation, recruitment, survival,
and degranulation of eosinophils. Indeed, during the last years, significant advances have …

The roles of eosinophils and interleukin‐5 in the pathophysiology of chronic rhinosinusitis with nasal polyps

P Gevaert, JK Han, SG Smith, AR Sousa… - International forum of …, 2022 - Wiley Online Library
Chronic rhinosinusitis with nasal polyps (CRSwNP) is generally associated with eosinophilic
tissue infiltration linked to type 2 inflammation and characterized by elevated levels of …

Eosinophils from physiology to disease: a comprehensive review

GA Ramirez, MR Yacoub, M Ripa… - BioMed research …, 2018 - Wiley Online Library
Despite being the second least represented granulocyte subpopulation in the circulating
blood, eosinophils are receiving a growing interest from the scientific community, due to their …

The intriguing role of interleukin 13 in the pathophysiology of asthma

G Marone, F Granata, V Pucino, A Pecoraro… - Frontiers in …, 2019 - frontiersin.org
Approximately 5–10% of asthmatic patients worldwide suffer from severe asthma.
Experimental and clinical studies have demonstrated that IL-13 is an important cytokine in …

Real‐world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta‐analysis

D Charles, J Shanley, SN Temple… - Clinical & …, 2022 - Wiley Online Library
Background Severe asthma is a major cause of morbidity. Some patients may benefit from
biological therapies. Most evaluations of these treatments are derived from randomized …

Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials

RA Panettieri, U Sjöbring, AM Péterffy… - The Lancet …, 2018 - thelancet.com
Background Tralokinumab is an anti-interleukin-13 human monoclonal antibody developed
for the treatment of severe, uncontrolled asthma. These clinical trials aimed to assess the …

The severe asthma network in Italy: findings and perspectives

E Heffler, F Blasi, M Latorre, F Menzella… - The Journal of Allergy …, 2019 - Elsevier
Background Severe Asthma Network in Italy (SANI) is a registry of patients recruited by
accredited centers on severe asthma. Objective To analyze epidemiological, clinical …

Neuraxial cytokines in pain states

G Gonçalves dos Santos, L Delay, TL Yaksh… - Frontiers in …, 2020 - frontiersin.org
A high-intensity potentially tissue-injuring stimulus generates a homotopic response to
escape the stimulus and is associated with an affective phenotype considered to represent …

Tezepelumab: a novel biological therapy for the treatment of severe uncontrolled asthma

G Marone, G Spadaro, M Braile, R Poto… - Expert opinion on …, 2019 - Taylor & Francis
Introduction: Thymic stromal lymphopoietin (TSLP) is overexpressed in the airways of severe
asthmatics and is an upstream cytokine that orchestrates inflammatory responses in asthma …

Neutrophil extracellular traps and neutrophil-derived mediators as possible biomarkers in bronchial asthma

G Varricchi, L Modestino, R Poto, L Cristinziano… - Clinical and …, 2022 - Springer
Neutrophils (PMNs) contain and release a powerful arsenal of mediators, including several
granular enzymes, reactive oxygen species (ROS) and neutrophil extracellular traps (NETs) …